Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma
Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma
复制标题
DOI：
10.1007/s00262-019-02303-1
复制
发表时间：
2019-04-01
影响因子：
5.8
通讯作者：
Wang, Yinghong
中科院分区：
文献类型：
--
作者：
Abu-Sbeih, Hamzah;Ali, Faisal S.;Wang, Yinghong
胃肠道(GI)免疫相关不良事件(IrAEs)通常限制免疫检查点抑制物(ICIS)的治疗，ICIS对转移性黑色素瘤非常有效。GI-irAEs对患者生存的独立影响还没有得到很好的研究。我们的目的是用多因素模型来评估Gi-irAEs对转移性黑色素瘤患者生存率的影响。随机选择了一些没有GI-irAEs的患者作为对照。用Kaplan-Meier曲线和对数等级检验估计未调整的生存时间。结果共纳入346例患者，173例GI-irAEs，124例(72%)接受免疫抑制治疗。在多因素COX回归分析中，ECOG2-3(HR 2.57，95%CI 1.44-4.57；P
BackgroundGastrointestinal (GI) immune-related adverse events (irAEs) commonly limit immune checkpoint inhibitors' (ICIs) treatment, which is very effective for metastatic melanoma. The independent impact of GI-irAEs on patients' survival is not well studied. We aimed to assess the impact of GI-irAEs on survival rates of patients with metastatic melanoma using multivariate model.MethodsThis is a retrospective study of patients with metastatic melanoma who developed GI-irAEs from 1/2010 through 4/2018. A number of randomized patients who did not have GI-irAEs were included as controls. Kaplan-Meier curves and log-rank test were used to estimate unadjusted survival durations. The Cox proportional hazards model was used to evaluate survival predictors; irAEs were included as time-dependent variables.ResultsA total of 346 patients were included, 173 patients had GI-irAEs; 124 (72%) received immunosuppression. In multivariate Cox regression, ECOG 2-3 (HR 2.57, 95%CI 1.44-4.57; P